← 返回

CAR-T 治疗中的数学模型与计算方法

英文原题:Mathematical models and computational approaches in CAR-T therapeutics.

查看英文原题

Mathematical models and computational approaches in CAR-T therapeutics.

PubMed 2025/08/01(内容时间) Front Immunol Q1 · IF 7(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

研究概要

我们提出了一个综合框架,利用这些模型推进 CAR-T 细胞疗法,弥合现有治疗方法与 CAR-T 工程及其临床应用全部潜力之间的差距。

中文摘要

合成生物学旨在工程化改造活体生物,以实现特定治疗用途。CAR-T 因具备灵活性、特异性、可预测性和可控性,已成为癌症治疗的突破性方法。CAR-T 通过基因改造 T 细胞以靶向肿瘤特异性抗原。然而,现有模型在时空分辨率方面不足,限制了疗法的安全性、成本效益和总体潜力,实体瘤治疗尤为如此。主体内容:本文探讨数学模型和计算技术如何改进 CAR-T 设计并预测治疗结局,重点关注抗原受体功能、治疗效力和潜在不良反应等关键因素。作者考察 CAR-T 细胞动力学及抗原结合的影响,并讨论克服抗原逃逸、CRS 和复发的策略。

作者提出利用这些模型推进 CAR-T 疗法的综合框架,以弥合现有治疗方法与 CAR-T 工程及其临床应用全部潜力之间的差距。

展开英文摘要原文

The field of synthetic biology aims to engineer living organisms for specific therapeutic applications, with CAR-T cell therapy emerging as a groundbreaking approach in cancer treatment due to its potential for flexibility, specificity, predictability, and controllability. CAR-T cell therapies involve the genetic modification of T cells to target tumor-specific antigens. However, challenges persist because the limited spatio-temporal resolution in current models hinders the therapy's safety, cost-effectiveness, and overall potential, particularly for solid tumors. MAIN BODY: This manuscript explores how mathematical models and computational techniques can enhance CAR-T therapy design and predict therapeutic outcomes, focusing on critical factors such as antigen receptor functionality, treatment efficacy, and potential adverse effects. We examine CAR-T cell dynamics and the impact of antigen binding, addressing strategies to overcome antigen escape, cytokine release syndrome, and relapse.

We propose a comprehensive framework for using these models to advance CAR-T cell therapy, bridging the gap between existing therapeutic methods and the full potential of CAR-T engineering and its clinical application.

论文信息

作者
Putignano G、Ruipérez-Campillo S、Yuan Z、Millet J、Guerrero-Aspizua S
第一作者单位
bioERGOtech, Taranto, Italy.Italy
通讯作者单位
Universidad Carlos III de Madrid, Departamento de Bioingeniería, Centro de Investigación Biomédica en Red de Enfermedades Raras-ISCIII, Instituto de Investigación Sanitaria Fundación Jiménez Díaz, Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Madrid, Spain.Spain
文献类型
综述
期刊
Frontiers in immunology2025
原文标识
PubMed 40821789 · DOI 10.3389/fimmu.2025.1581210